A phase 1 trial exploring the investigational antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd; DS-1062) showed the agent’s ability to induce antitumor activity as well as produce an acceptable safety profile in patients with previously treated advanced or metastatic non–small cell lung cancer (NSCLC), results of which were presented at the 2020 World Conference on Lung Cancer (WCLC) Singapore.1
Preliminary efficacy data from the TROPION-PanTumor01 trial (NCT03401385) showed that datopotamab deruxtecan elicited an overall response rate of 23% (n = 9) at a dose of 4 mg/kg (n = 40), 21% (n = 8) at 6 mg/kg (n = 39), and 25% (n = 20) at 8 mg/kg (n = 80) per blinded independent central review. Confirmed complete or partial responses were observed in 7, 6, and 19 patients, respectively.
Additionally, 2 patients who received the 4 mg/kg dose, 2 patients who received the 6…
